ExodusPoint Capital Management LP Has $1.23 Million Stock Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

ExodusPoint Capital Management LP grew its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 98.4% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 105,827 shares of the company's stock after acquiring an additional 52,486 shares during the quarter. ExodusPoint Capital Management LP owned about 0.10% of Intellia Therapeutics worth $1,234,000 as of its most recent SEC filing.

A number of other institutional investors also recently made changes to their positions in NTLA. ARK Investment Management LLC raised its holdings in shares of Intellia Therapeutics by 2.3% in the 4th quarter. ARK Investment Management LLC now owns 12,536,386 shares of the company's stock worth $146,174,000 after purchasing an additional 280,946 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of Intellia Therapeutics by 5.8% in the fourth quarter. Vanguard Group Inc. now owns 10,190,053 shares of the company's stock worth $118,816,000 after purchasing an additional 562,249 shares in the last quarter. State Street Corp grew its holdings in shares of Intellia Therapeutics by 17.9% during the 3rd quarter. State Street Corp now owns 5,143,534 shares of the company's stock valued at $105,700,000 after acquiring an additional 780,754 shares in the last quarter. Regeneron Pharmaceuticals Inc. acquired a new position in shares of Intellia Therapeutics in the fourth quarter worth $43,177,000. Finally, Geode Capital Management LLC raised its holdings in shares of Intellia Therapeutics by 2.0% during the fourth quarter. Geode Capital Management LLC now owns 2,389,240 shares of the company's stock worth $27,865,000 after acquiring an additional 45,930 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Trading Down 2.1 %

NTLA traded down $0.16 on Tuesday, hitting $7.35. 681,224 shares of the stock traded hands, compared to its average volume of 2,319,951. The business has a fifty day moving average price of $9.09 and a two-hundred day moving average price of $12.44. Intellia Therapeutics, Inc. has a 52 week low of $5.90 and a 52 week high of $28.18. The firm has a market capitalization of $760.33 million, a PE ratio of -1.35 and a beta of 2.23.

Wall Street Analyst Weigh In

NTLA has been the subject of a number of recent research reports. Oppenheimer cut their price target on Intellia Therapeutics from $60.00 to $40.00 and set an "outperform" rating for the company in a research note on Monday, January 13th. The Goldman Sachs Group reiterated a "sell" rating and issued a $9.00 target price on shares of Intellia Therapeutics in a research note on Friday, February 28th. Barclays cut their price target on shares of Intellia Therapeutics from $55.00 to $26.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Truist Financial lowered their target price on shares of Intellia Therapeutics from $90.00 to $50.00 and set a "buy" rating on the stock in a research report on Tuesday, March 4th. Finally, Wells Fargo & Company cut their target price on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating on the stock in a report on Friday, February 28th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $37.56.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.